Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Inflammatory bowel disease (IBD) is associated with various extraintestinal manifestations. We aimed to identify comorbidities in IBD and the timing of their development to provide potentially useful insight into the associations with IBD.

Methods: We conducted a population and disease-wide phenomic association study in IBD, using >6 million International Classification of Diseases, Tenth Revision coded healthcare contacts from 10 years before and up-to 17 years after IBD diagnosis to investigate associations with 1,583 comorbidities. To explore diseases with potential etiological significance, we compared association in the prediagnostic and the postdiagnostic periods. We corrected also for multiple-testing. These estimates were validated with publicly available data from Finland.

Results: We identified 312 significant associations with 125 appearing before diagnosis. Risk of extraintestinal manifestations was increased up to 10 years before IBD diagnosis, such as psoriasis (OR CD : 2.58 95% confidence interval: [2.00-3.31]; OR UC : 1.54 [1.26-1.88]) and reactive arthropathies (OR CD : 2.07 [1.42-2.96]; OR UC : 1.42 [1.08-1.84]). Risk of cardiometabolic and neuropsychological disorders was increased both prediagnostically and postdiagnostically. Potential treatment sequelae, such as osteoporosis (HR CD : 2.56 [2.30-2.86]; HR UC : 1.92 [1.79-2.07]) were primarily seen postdiagnostically. In only 15.7% (44/281) and 11.4% (35/301) of comorbidities in Crohn's disease and ulcerative colitis, respectively, did we observe heterogeneity between Denmark and Finland.

Discussion: Findings demonstrate that IBD is a multisystemic disease, particularly manifesting with metabolic, immune, and neuropsychological disorders, up to 10 years before diagnosis. We find evidence for the generality of these findings with an international comparison. Diseases of etiological interest warrant further investigation.

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000003673DOI Listing

Publication Analysis

Top Keywords

inflammatory bowel
8
bowel disease
8
prediagnostic postdiagnostic
8
phenomic association
8
association study
8
extraintestinal manifestations
8
years ibd
8
ibd diagnosis
8
neuropsychological disorders
8
ibd
6

Similar Publications

Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.

Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.

View Article and Find Full Text PDF

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by disruption of intestinal barrier function and complex inflammatory manifestations locally and systemically. Although anti-tumor necrosis factor-α (TNF-α) agents such as Infliximab (IFX) are effective in treating IBD, their intestinal tissue concentration has been regarded as determinant of therapeutic efficacy while was restrained by the large molecular weight. Considering the enhanced expression of human neonatal Fc receptor (hFcRn) in UC tissues, we attempted to deliver the therapeutic entity of IFX into UC tissues by developing a novel dual-acting IFX Fab-F8 (IFX-F8) fusion protein for UC treatment.

View Article and Find Full Text PDF

Prim-O-glucosylcimifugin attenuates intestinal fibrosis by modulating TGF-β/MAPK signaling and ECM remodeling.

Life Sci

September 2025

KM Convergence Research Division, Korea Institute of Oriental Medicine, Republic of Korea; Korean Convergence Medical Science Major, KIOM School, University of Science & Technology (UST), Daejeon, 34054, Republic of Korea. Electronic address:

Background: Intestinal fibrosis is a severe and progressive complication of inflammatory bowel disease (IBD), particularly Crohn's disease (CD), for which no effective anti-fibrotic therapies currently exist.

Purpose: This study aimed to investigate the anti-fibrotic efficacy and underlying mechanisms of Prim-O-glucosylcimifugin (POG), a natural chromone derivative, in TGF-β1-stimulated human intestinal fibroblasts.

Methods: Fibrosis was modeled in human intestinal fibroblast cell lines (CCD-18Co) and human primary intestinal myofibroblasts (HIMF) using TGF-β1.

View Article and Find Full Text PDF

Background: Intestinal cells receive incoming signals from neighboring cells and microbial communities. Upstream signaling pathways transduce these signals to reach transcription factors (TFs) that regulate gene expression. In inflammatory bowel disease (IBD), most single nucleotide polymorphisms (SNPs) are in non-coding genomic regions containing TF binding sites.

View Article and Find Full Text PDF

Background & Aims: Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes.

View Article and Find Full Text PDF